Navigation Links
Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement
Date:10/20/2009

BOTHELL, Wash., Oct. 20 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, entered into an exclusive agreement with OMRON Healthcare distribute Omron's vital signs and spot check monitors under the Cardiac Science brand in the United States and Canada. OMRON Healthcare is a subsidiary of OMRON Corporation, the $7-billion global leader in the sensing and control market and the global leader in blood pressure monitoring with sales of more than 100 million blood pressure units worldwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO )

"This deal leverages our industry-leading distribution capabilities. OMRON is an outstanding company with an excellent reputation for quality," said Dave Marver, Cardiac Science's president and chief executive officer. "They are an ideal partner to help us enter the North American vital signs market."

"When we looked to expand our U.S. based sales into the diagnostic market for healthcare professionals," said Bob Kondraske, chief operating officer for OMRON Healthcare, Inc., "we needed a partner with deep industry knowledge and solid distribution. Cardiac Science is a leader in ECG, Holter, cardiac stress, and automated external defibrillation sales into the physician office. In addition, they have a strong direct sales force in the hospital market. They've demonstrated their commitment and skill selling into both marketplaces - which is exactly what we needed."

Vital signs monitors sold under the exclusive agreement are available for sale next Monday under the Cardiac Science name, while clearly featuring the accuracy of the OMRON technology. "This allows customers to recognize the strengths of both brands, and know they're purchasing from a partnership comprising two world leaders," Kondraske added.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, vital signs monitors, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, Facebook at http://budurl.com/CSonFB, and YouTube at http://budurl.com/CSonYT.

About OMRON Healthcare

Omron Healthcare, Inc., located in Bannockburn, IL, is the North and South American sales and marketing office of Omron Healthcare Group, a leading manufacturer and distributor of blood pressure monitors for home use. With more than 100 million monitors sold worldwide to date, Omron Healthcare Group was the first to introduce manual and digital blood pressure monitors into the home healthcare market. Omron Healthcare offers innovative products and medical devices for use in sites ranging from hospitals to the home in the blood pressure monitoring, fitness diagnostics, thermometry, and respiratory categories. Omron Healthcare markets clinically proven products that provide accurate health information to consumers and physicians and support positive lifestyle changes and health improvement. For information, call 847.247.5637 or visit www.omronhealthcare.com or www.omronwebstore.com.

Forward Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's expectations regarding the impact of the agreement with OMRON Healthcare on Cardiac Science's growth and regarding future distribution partnerships. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in Cardiac Science Corporation's Annual Report on Form 10-K for the year ended December 31, 2008 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2009. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For more information,

    -------------------------------------------------------------------------
    Cardiac Science Contact:        Investor Contact:    Media Contact:
    ------------------------        -----------------    --------------------
    Mike Matysik                    Matt Clawson         Christopher Gale
    Cardiac Science Corporation     Allen & Caron        EVC Group Inc.
    Senior Vice President and CFO   949.474.4300         646.201.5431
    425.402.2009                    matt@allencaron.com  203.570.4681
                                                         cgale@evcgroup.com
    -------------------------------------------------------------------------
    OMRON Healthcare Contact:
    -------------------------
    Johnna Purcell
    OMRON Healthcare
    847.247.5637

    CSCX-G

    SOURCE Cardiac Science Corporation


    '/>"/>

SOURCE Cardiac Science Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testing
2. Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression
3. Treatment Shows Excellent Results for Providence Tarzana Patients Following Cardiac Arrest
4. Worlds First Cardiac Adult Stem Cell Patient Receives Infusion
5. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
6. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
7. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
8. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
9. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
10. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
11. Cardiac Disease in Women Remains Untreated for Decades
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 19, 2017 According to a ... cryotherapy is set to witness a CAGR of 6.5% during the ... will continue to be the leading market for cryotherapy ... ... are emphasizing on ensuring affordable and adequate supply of gas in ...
(Date:1/19/2017)... BOCA RATON, Fla. , Jan. 19, 2017 ... ), a medical device company specializing in the ... conditions, such as keloids, with superficial radiation therapy, ... quarter and full year 2016 financial results on Thursday, ... The Company will hold a conference call ...
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
Breaking Medicine Technology:
(Date:1/19/2017)... Florida (PRWEB) , ... January 19, 2017 , ... ... dollar 5,000 SF expansion and facility enhancement of their 503A compounding pharmacy located ... meet the growing demand of physicians and patients throughout the United States for ...
(Date:1/19/2017)... , ... January 19, 2017 , ... WhoHaha , ... up with the American Heart Association (AHA) to produce a three-part video series that ... will debut as part of the launch of AHA’s Healthy For Good™ movement, which ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it will be co-hosting a ... innovative excipients and drug delivery solutions to health industries worldwide. The one day ...
(Date:1/19/2017)... ... January 19, 2017 , ... In ... administered fillers that resulted in severe facial disfiguration. After four frightening years of ... doctors at UCLA Medical Center, who removed the substances in a partial facial ...
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate Medical Academy (UMA) is ... passionate about making a difference in the lives of the next generation of ... nonprofit healthcare educational institution, has more than 30,000 alumni and employs more than ...
Breaking Medicine News(10 mins):